Altre lingue RaQualia Pharma Inc.

Azioni

4579

JP3967150008

Prodotti farmaceutici

Tempo differito Japan Exchange Altri mercati azionari 07:30:00 12/03/2026			Variaz. 5gg	Var. 1 gen.
879,00 ^JPY	-3,83%		-0,90%	-12,97%

13/02	RaQualia Pharma Inc. pubblica i risultati finanziari per l'esercizio chiuso al 31 dicembre 2025	CI
13/02	Raqualia Pharma Inc. Fornisce le Previsioni Consolidate sugli Utili per l'Anno che Termina il 31 Dicembre 2025	CI

Altre lingue

13/02	RaQualia Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
13/02	Raqualia Pharma Inc. Provides Consolidated Earnings Guidance for Year Ending December 31, 2025
29/01	RaQualia Pharma Inc. announced that it has received ¥1.4112013 billion in funding from HK inno.N Corporation
12/12	RaQualia Pharma Inc. announced that it expects to receive ¥1.4112013 billion in funding from HK inno.N Corporation
22/09/25	RaQualia Pharma Inc.(TSE:4579) dropped from S&P Global BMI Index
15/05/25	D.Western Therapeutics Institute, Inc. Announces Results of Joint Research with Raqualia Pharma Inc
18/04/25	RaQualia Pharma Inc. announced that it has received ¥1.0290637 billion in funding from HK inno.N Corporation
25/03/25	HK inno.N Acquires Stake in Japan's RaQualia Pharma
21/03/25	RaQualia Pharma Inc. announced that it expects to receive ¥1.0290637 billion in funding from HK inno.N Corporation
14/02/25	Raqualia Pharma Inc. Provides Earnings Guidance for Year Ending December 31, 2025
26/03/24	RaQualia Pharma Inc. completed the acquisition of FIMECS, Inc. from Yusuke Tominari, Kamakanae, Nissay Capital No. 11 Investment Limited Partnership managed by Nissay Capital Co., Ltd., ANRI No. 4 Fund managed by ANRI and others.
14/02/24	RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2024
14/02/24	RaQualia Pharma Inc. agreed to acquire FIMECS, Inc. from Nissay Capital No. 11 Investment Limited Partnership and Nissay Capital Co., Ltd. for ¥4.5 billion.
10/08/23	RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2023
12/06/23	Constipation Pipeline, Clinical Trials, and Key Companies\|Companies-Anji Pharma, Yuhan, Theravance Biopharma
15/05/23	RaQualia Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
15/05/23	RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2023
14/02/23	RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023
05/01/23	RaQualia Pharma Inc. announced that it has received ¥805.6125 million in funding from CVI Investments, Inc.
20/12/22	RaQualia Pharma Inc. announced that it expects to receive Ã‘805.6125 million in funding from CVI Investments, Inc.
11/11/22	Raqualia Pharma Inc. Provides Consolidated Earnings Guidance for Year Ending December 31, 2022
15/08/22	RaQualia Pharma : Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending December 31, 2022 (JGAAP)
15/08/22	RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2022
15/02/22	RaQualia Pharma : (Delayed)Summary of Consolidated Financial Results for the Fiscal Year Ended December 31, 2021 (JGAAP)
15/02/22	RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022